ArticleFrontiers in medicine2025
Plausibility of super high-flux dialyzer reuse in maintenance hemodialysis.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dialyzer reuse in traditional hemodialysis (HD) has been demonstrated to reduce medical waste and manufacturing costs compared to a single-use strategy. HD techniques nowadays have increasingly shifted to convective therapies, such as HD with super high-flux dialyzers (SHF), to remove larger uremic toxins and improve outcomes. However, studies on the reuse of SHF are lacking. Successful reuse of SHF may lower the economic and environmental burdens while maintaining superior clinical outcomes. Objective: To compare the removal of uremic toxins and safety after reuse of SHF. Methods: ELISIO-21 HX SHF were reprocessed with peracetic acid for up to 15 reuse times in stable thrice-a-week HD patients in King Chulalongkorn Memorial Hospital. The reduction ratio (RR) or clearance of β2-microglobulin (β2M, 11.8 kDa), α1-microglobulin (α1M, 31 kDa), λ-free light chain (λFLC, 45 kDa), and protein-bound indoxyl sulfate were compared between the 1st, 2nd, 5th, 10th, and 15th reuse times. Dialysate albumin loss and the change in serum albumin were assessed. Results: A total of 15 dialyzers were investigated from 5 patients. The β2M clearance and RR were comparable between the 1st and 15th use (127.2 ± 18.3 mL/min vs. 114.4 ± 17.2 mL/min, Conclusion: Super high-flux dialyzers reuse is a safe and promising method to reduce medical waste and manufacturing costs while maintaining the benefits of this novel HD technique. We also suggest appropriate cut-off points for the change in RR of the middle-molecule uremic toxin after reuse to prevent significant impairment in solute clearances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.